Tag: Cancer: Prostate

Prostate cancer-specific mortality rates 2.4 and 4.7 percent for unfavorable intermediate-risk and high-risk GG1

Black men fare worse in confirmatory testing and face lower likelihood of potential overtreatment

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to six times more likely to die of other causes

Findings show promise compared with usual care but warrant a larger trial, the authors say

Patient-reported outcomes appear to be similar to postoperative conventionally fractionated radiotherapy

Absence of progression correctly identified by subsequent MRI in nearly 95, 90, 70 percent of men with grade group 0, 1, 2, respectively

A more recent prostatectomy was associated with lower likelihood of pGG1 prostatectomy in two cohorts

UHF noninferior to conventionally fractionated radiotherapy for men with intermediate- to high-risk localized disease

PROSTOX predicts late genitourinary toxicity, yielding area under the curve of 0.76

Targeted screening to participants in ≥90th percentile of polygenic risk score results in detection of cancer warranting clinical management in 55.1 percent